Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 3

Дисфункциональные вегетативные расстройства в фокусе невролога
М.Ю. Максимова, А.С. Галанина

References

1. Arbanas G. Anxiety and somatoform disorders. In: Psychiatry and sexual medicine. Lew-Starowicz M, Giraldi A, Krüger T, editors. Heidelberg; NY; Dordrecht; London: Springer, Cham; 2021: 261-76.
2. De Gucht V, Fischler B. Somatization: a critical review of conceptual and methodological issues. Psychosomatics 2002 Jan-Feb;43(1):1-9.
3. Hüsing P, Löwe B, Toussaint A. Comparing the diagnostic concepts of ICD-10 somatoform disorders and DSM-5 somatic symptom disorders in patients from a psychosomatic outpatient clinic. Journal of Psychosomatic Research 2018 Oct;113:74-80.
4. olde Hartman TC, Borghuis MS, Lucassen PL, van de Laar FA, Speckens AE, van Weel C. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. Journal of Psychosomatic Research 2009 May;66(5):363-77.
5. Scarella TM. Somatoform disorders. In: Neurology and psychiatry of women. O’Neal M, editor. Heidelberg; NY; Dordrecht; London: Springer, Cham; 2019: 47-67.
6. Obimakinde AM, Ladipo MM, Irabor AE. Familial and socio-economic correlates of somatisation disorder. African Journal of Primary Health Care & Family Medicine 2015 May;7(1):746.
7. Swartz M, Landerman R, Blazer D, George L. Somatization symptoms in the community: a rural/urban comparison. Psychosomatics 1989 Winter;30(1):44-53.
8. Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. Journal of General Internal Medicine 2001 Apr;16(4):266-75.
9. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Archives of General Psychiatry 2005 Aug;62(8):903-10.
10. McAndrew LM, Phillips LA, Helmer DA, Maestro K, Engel CC, Greenberg LM, Anastasides N, Quigley KS. High healthcare utilization near the onset of medically unexplained symptoms. Journal of Psychosomatic Research 2017 Jul;98:98-105.
11. Scarella TM, Laferton JA, Ahern DK, Fallon BA, Barsky A. The relationship of hypochondriasis to anxiety, depressive, and somatoform disorders. Psychosomatics 2016 Mar-Apr;57(2):200-7.
12. Berna C, Leknes S, Holmes EA, Edwards RR, Goodwin GM, Tracey I. Induction of depressed mood disrupts emotion regulation neurocircuitry and enhances pain unpleasantness. Biological Psychiatry 2010 Jun;67(11):1083-90.
13. Dijkstra-Kersten SM, Sitnikova K, van Marwijk HW, Gerrits MM, van der Wouden JC, Penninx BW, van der Horst HE, Leone SS. Somatisation as a risk factor for incident depression and anxiety. Journal of Psychosomatic Research 2015 Dec;79(6):614-9.
14. Oyama O, Paltoo C, Greengold J. Somatoform disorders. American Family Physician 2007 Nov;76(9):1333-8.
15. Kellner R. Psychosomatic syndromes, somatization and somatoform disorders. Psychotherapy and Psychosomatics 1994;61(1-2):4-24.
16. Desai G, Chaturvedi SK. Do diagnostic criteria for psychosomatic research explain diagnosis of medically unexplained somatic symptoms. Psychotherapy and Psychosomatics 2016;85(2):121-2.
17. Joustra ML, Janssens KA, Bültmann U, Rosmalen JG. Functional limitations in functional somatic syndromes and well-defined medical diseases. Results from the general population cohort LifeLines. Journal of Psychosomatic Research 2015 Aug;79(2):94-9.
18. Mukharovskaya IR, Markov MV, Abdryakhimova TsB, Kleban KI, Sapon DM. Psychosomatic disorders in clinical practice. Journal of Education, Health and Sport 2019;9(12):181-5.
19. Russell G, Lightman S. The human stress response. Nature Reviews. Endocrinology 2019 Sep;15(9):525-34.
20. Aguilera G, Rabadan-Diehl C, Kiss A, Ochedalski T. Vasoactive hormones and regulation of the hypothalamic-pituitary-adrenal axis. In: Catecholamine research. Advances in behavioral biology. Nagatsu T, Nabeshima T, McCarty R, Goldstein DS, editors. Boston, MA: Springer; 2002; 281-4.
21. Mello AF, Mello MF, Carpenter LL, Price LH. Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Revista Brasileira de Psiquiatria 2003 Oct;25(4):231-8.
22. Rief W, Barsky AJ. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 2005 Nov;30(10):996-1002.
23. Wichmann S, Kirschbaum C, Böhme C, Petrowski K.Cortisol stress response in post-traumatic stress disorder, panic disorder, and major depressive disorder patients. Psychoneuroendocrinology 2017 Sep;83:135-41.
24. Claassen-van Dessel N, van der Wouden JC, Dekker J, Rosmalen JGM, van der Horst HE. The cross-sectional relation between medically unexplained physical symptoms (MUPS) and the Cortisol Awakening Response. Journal of Psychosomatic Research 2017 Aug;99:130-6.
25. Zamorano M, Ledesma-Colunga MG, Adán N, Vera-Massieu C, Lemini M, Méndez I, Moreno-Carranza B, Neumann ID, Thebault S, Martínez de la Escalera G, Torner L, Clapp C. Prolactin-derived vasoinhibins increase anxiety- and depression-related behaviors. Psychoneuroendocrinology 2014 Jun;44:123-32.
26. Pavlova TA, Dorovskikh IV, Gorobets LN. Neuroendocrine aspects of pathogenesis and psychopharmacotherapy of panic disorder. Psychiatry 2016;72:55-69 (In Russian).
27. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders CNS Drugs. 2001;15(10):797-817.
28. Torgersen S. Genetics of somatoform disorders. Archives of General Psychiatry 1986;43(5):502-5.
29. Guze SB. Genetics of Briquet’s syndrome and somatization disorder. A review of family, adoption, and twin studies. Annals of Clinical Psychiatry 1993 Dec;5(4):225-30.
30. Gil FP, Giegling I, Reisch N, Hartmann AM, Konte B, Schwarz MJ, Rujescu D. Association of somatoform disorder symptoms with genetic variants potentially involved in the modulation of nociception. Psychiatric Genetics 2011 Feb;21(1):50.
31. Jakobi J, Bernateck M, Tran AT, Holm L, Volkmann L, Buers D, Karst M, Stuhrmann M. Catechol-O-methyltransferase gene polymorphisms are not associated with multisomatoform disorder in a group of German multisomatoform disorder patients and healthy controls. Genetic Testing and Molecular Biomarkers 2010 Jun;14(3):293-7.
32. Koh KB, Kim CH, Choi EH, Lee YJ, Seo WY. Effect of tryptophan hydroxylase gene polymorphism on aggression in major depressive disorder and undifferentiated somatoform disorder. The Journal of Clinical Psychiatry 2012;73(5):e574-9.
33. Huang B, Jiang C, Zhang R. Epigenetics: the language of the cell? Epigenomics 2014 Feb;6(1):73-88.
34. Shimada-Sugimoto M, Otowa T, Miyagawa T, Umekage T, Kawamura Y, Bundo M, Iwamoto K, Tochigi M, Kasai K, Kaiya H, Tanii H, Okazaki Y, Tokunaga K, Sasaki T. Epigenome-wide association study of DNA methylation in panic disorder. Clinical Epigenetics 2017;9:6.
35. Murphy TM, O’Donovan A, Mullins N, O’Farrelly C, McCann A, Malone K. Anxiety is associated with higher levels of global DNA methylation and altered expression of epigenetic and interleukin-6 genes. Psychiatric Genetics 2015 Apr;25(2):71-8.
36. Emeny RT, Baumert J, Zannas AS, Kunze S, Wahl S, Iurato S, Arloth J, Erhardt A, Balsevich G, Schmidt MV, Weber P, Kretschmer A, Pfeiffer L, Kruse J, Strauch K, Roden M, Herder C, Koenig W, Gieger C, Waldenberger M, Peters A, Binder EB, Ladwig KH. Anxiety associated increased CpG methylation in the promoter of Asb1: a translational approach evidenced by epidemiological and clinical studies and a murine model. Neuropsychopharmacology 2018 Jan;43(2):342-53.
37. De Berardis D, Campanella D, Nicola S, Gianna S, Alessandro C, Chiara C, Valchera A, Marilde C, Salerno RM, Ferro FM. The impact of alexithymia on anxiety disorders: a review of the literature. Current Psychiatry Reviews 2008;4(2):80-6.
38. Waller E, Scheidt CE. Somatoform disorders as disorders of affect regulation: a development perspective. International Review of Psychiatry 2006 Feb;18(1):13-24.
39. Subic-Wrana C, Beutel ME, Knebel A, Lane RD. Theory of mind and emotional awareness deficits in patients with somatoform disorders. Psychosomatic Medicine 2010 May;72(4):404-11.
40. Perez DL, Barsky AJ, Vago DR, Baslet G, Silbersweig DA. A neural circuit framework for somatosensory amplification in somatoform disorders. The Journal of Neuropsychiatry and Clinical Neurosciences 2015;27(1):e40-50.
41. Moreno MA, Jelenchick LA, Christakis DA. Problematic internet use among older adolescents: a conceptual framework. Computers in Human Behavior 2013;29(4):1879-87.
42. Rosen LD, Cheever NA, Carrier L. iDisorder: understanding our obsession with technology and overcoming its hold on us. New York, NY: Palgrave Macmillan; 2012. 246 p.
43. Ovchinnikov AA, Sultanova AN. Features of stress character in patients with neurotic disorders. Journal of Siberian Medical Sciences 2015;3:35 (In Russian).
44. Delvecchio G, Rossetti MG, Caletti E, Arighi A, Galimberti D, Basilico P, Mercurio M, Paoli R, Cinnante C, Triulzi F, Altamura AC, Scarpini E, Brambilla P. The neuroanatomy of somatoform disorders: a magnetic resonance imaging study. Psychosomatics 2019 May-Jun;60(3):278-88.
45. den Boeft M, Claassen-van Dessel N, van der Wouden JC. How should we manage adults with persistent unexplained physical symptoms? British Medical Journal 2017 Feb;356:j268.
46. Usova NN, Galinovskaya NV, Latysheva VYa. Correction of vegetative dystonia syndrome in children and adolescents by Mildronate®. Recipe 2007;2(52):91-4 (In Russian).
47. Statsenko ME, Nedogoda SV, Turkina SV, Tyshchenko IA, Poletayeva LV, Tsoma VV, Ledyayeva AA, Chumachok EV. Asthenic disorders in elderly patients with arterial hypertension: management potential of meldonium. Rational Pharmacotherapy in Cardiology 2013;9(1):25-30 (In Russian).
48. Tanashyan MM, Maksimova MYu, Shabalina AA, Fedin PA, Medvedev RB, Bolotova TA. Chronic cerebrovascular diseases and neuroprotection: clinical efficacy of meldonium (mildronate). SS Korsakov Journal of Neurology and Psychiatry 2020;120(10):14-21 (In Russian).
49. Hedman E, Axelsson E, Andersson E, Lekander M, Ljótsson B. Exposure-based cognitive-behavioural therapy via the internet and as bibliotherapy for somatic symptom disorder and illness anxiety disorder: randomised controlled trial. The British Journal of Psychiatry 2016 Nov;209(5):407-13.
50. Burton C. Beyond somatisation: a review of the understanding and treatment of medically unexplained physical symptoms (MUPS). The British Journal of General Practice 2003 Mar;53(488):231-9.
51. Allen LA, Woolfolk RL, Escobar JI, Gara MA, Hamer RM. Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. Archives of Internal Medicine 2006 Jul;166(14):1512-8.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]